<p>Treatment with the Bacillus Calmette-Guerin (BCG) vaccine—which prevents tuberculosis—is associated with a reduced risk of Alzheimer's disease and related dementias, according to a study.</p>.<p>The BCG vaccine has been found to offer multiple beneficial effects, and is currently a recommended therapy for non–muscle-invasive bladder cancer, the researchers said.</p>.<p>The team at Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH), US followed 6,467 individuals for up to 15 years after they were diagnosed with non–muscle-invasive bladder cancer.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/international/world-news-politics/ukraine-sudan-conflicts-fuel-alarming-surge-in-tuberculosis-1217047.html" target="_blank">Ukraine, Sudan conflicts fuel alarming surge in tuberculosis</a></strong><br /><br />The group included 3,388 patients who underwent BCG vaccine treatment and 3,079 who served as controls, matched by factors such as age, sex, and medical co-morbidities.</p>.<p>During follow-up, the study published in the journal JAMA Network Open found that 202 patients in the BCG vaccine group and 262 in the control group developed Alzheimer's disease and related dementias.</p>.<p>The incidence was 8.8 per 1,000 person-years and 12.1 per 1,000 person-years in the respective groups, the researchers said. Analyses revealed that treatment with the BCG vaccine was associated with a 20 per cent lower risk of Alzheimer's disease and related dementias.</p>.<p>The protective association was greater in patients aged 70 years or older. Additionally, during follow-up, 751 patients in the BCG vaccine group and 973 in the control group died.</p>.<p>Treatment with BCG vaccine was associated with a 25 per cent lower risk of death, according to the researchers.</p>.<p>"A vaccine like BCG, if proven effective, is a perfect example of a cost-effective, population-health–based solution to a devastating illness like Alzheimer's disease," said Weinberg.</p>.<p>"We are shifting our focus towards studying the potential benefits of BCG vaccination of older adults in Alzheimer's disease–related clinical trialsm," he added.</p>.<p>Weinberg and his colleagues noted that if a causal link is found, it will be important to understand the mechanisms involved, adding the BCG vaccine's effects on the immune system may play a role.</p>
<p>Treatment with the Bacillus Calmette-Guerin (BCG) vaccine—which prevents tuberculosis—is associated with a reduced risk of Alzheimer's disease and related dementias, according to a study.</p>.<p>The BCG vaccine has been found to offer multiple beneficial effects, and is currently a recommended therapy for non–muscle-invasive bladder cancer, the researchers said.</p>.<p>The team at Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH), US followed 6,467 individuals for up to 15 years after they were diagnosed with non–muscle-invasive bladder cancer.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/international/world-news-politics/ukraine-sudan-conflicts-fuel-alarming-surge-in-tuberculosis-1217047.html" target="_blank">Ukraine, Sudan conflicts fuel alarming surge in tuberculosis</a></strong><br /><br />The group included 3,388 patients who underwent BCG vaccine treatment and 3,079 who served as controls, matched by factors such as age, sex, and medical co-morbidities.</p>.<p>During follow-up, the study published in the journal JAMA Network Open found that 202 patients in the BCG vaccine group and 262 in the control group developed Alzheimer's disease and related dementias.</p>.<p>The incidence was 8.8 per 1,000 person-years and 12.1 per 1,000 person-years in the respective groups, the researchers said. Analyses revealed that treatment with the BCG vaccine was associated with a 20 per cent lower risk of Alzheimer's disease and related dementias.</p>.<p>The protective association was greater in patients aged 70 years or older. Additionally, during follow-up, 751 patients in the BCG vaccine group and 973 in the control group died.</p>.<p>Treatment with BCG vaccine was associated with a 25 per cent lower risk of death, according to the researchers.</p>.<p>"A vaccine like BCG, if proven effective, is a perfect example of a cost-effective, population-health–based solution to a devastating illness like Alzheimer's disease," said Weinberg.</p>.<p>"We are shifting our focus towards studying the potential benefits of BCG vaccination of older adults in Alzheimer's disease–related clinical trialsm," he added.</p>.<p>Weinberg and his colleagues noted that if a causal link is found, it will be important to understand the mechanisms involved, adding the BCG vaccine's effects on the immune system may play a role.</p>